Sunday, June 7, 2026, is National Cancer Survivors Day — the annual observance that began on June 5, 1988, and is held on the first Sunday of June to honor the 18 million Americans living beyond a cancer diagnosis. It is a day that typically offers hope in abstract terms: statistics of five-year survival rates and remission milestones. This year, it arrives against the backdrop of what oncologists at the American Society of Clinical Oncology annual meeting in Chicago described on May 31 as a 'game-changing' development — a Phase 3 trial result that has redefined what survival means for patients with one of the deadliest cancers in medicine. For the oncology community in Dallas–Fort Worth, and for the patients at UT Southwestern Medical Center's Harold C. Simmons Comprehensive Cancer Center and Baylor Scott & White Health who will be asking their physicians about this drug in the coming weeks, the news from ASCO is not abstract. It is personally consequential.
The drug is daraxonrasib, a pan-RAS inhibitor developed by Revolution Medicines. In the RASolute 302 Phase 3 trial, it nearly doubled overall survival for patients with metastatic pancreatic cancer who had already received prior treatment — extending median overall survival from 6.7 months to 13.2 months. The risk of death was reduced by 60%. One-third of patients experienced at least a 20% reduction in tumor size. Dr. Brian Wolpin, the lead investigator, received a standing ovation from normally reserved researchers and physicians when he presented the results. That reaction — from a room of people who have spent careers navigating the grim statistics of pancreatic cancer — tells you more about the significance of these findings than any statistical summary can.
